Alvotech & JAMP Pharma Expands its 2020 Agreement for Two Biosimilar Candidates in Canada
- The collaboration expanded to add 2 biosimilar candidates to bring more affordable biologics to patients from Alvotech’s pipeline i.e., AVT16 for immunology & AVT33 for oncology. The companies have signed the agreement in Jan 2020 for 5 biosimilar candidates in the Canadian market
- JAMP Pharma to get exclusive commercialization right for Alvotech’s biosimilars in Canada & uses JAMP Pharma’s strong sales, marketing capabilities, and experience for new biosimilars. Alvotech will lead the development & commercialization of the biosimilar candidates.
- The companies launched a patient support program i.e., BIOJAMP & JAMP Care that provides access to patients and caregivers transitioning to lower-cost biosimilar therapies
Ref: Globenewswire | Image: Alvotech
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.